Ransom looking for pharma manufacturing arm sale
Healthcare products company William Ransom & Son has finally published its financial results for the year ended March 31, 2008, and provided an update on efforts to turn around the troubled business.
Archives for December 23, 2008
Covance sees dip in tox, pharmacology demand in Q4
Covance has cut its financial projections for 2008 and 2009 after seeing softening demand for its early-stage services, including toxicology and clinical pharmacology.
In vitro test ‘could prevent another Northwick Park‘
Simple preclinical experiments should be able to predict whether immunotherapeutic medicines are safe to advance to preclinical testing in humans and avoid the Northwick Park trial that left six healthy volunteers hospitalised.
The big five of 2008
in-PharmaTechnologist takes a look back over the past 12 months, rounding up our five most read stories of the year.
FDA contract a fillip for Entelos
In silico R&D specialist Entelos has entered into an agreement with the US Food and Drug Administration to use its PhysioLab to assess the safety and efficacy of cardiovascular drugs.
Peregrine unit Avid sees revenues decline in Q2
US drugmaker and contract manufacturer Peregrine narrowed its losses in the second fiscal quarter ending October 31, as a result of cost-cutting measures.
Schott shrugs off downturn with sales, earnings hike
Germany’s Schott Glass posted a 4 per cent increase in revenues during fiscal 2008, bringing in €2.23bn across its divisions.
Pfizer licenses gene knockout tech
Pfizer has gained a license for the use of certain ZFP Nuclease (ZFNs) reagents from Sangamo BioSciences, which it will use to modify Chinese Hamster Ovary (CHO) cell lines.
EU wholesalers express concern with pharma package
The European Association of Pharmaceutical Full-line Wholesalers (GIRP) says it has concerns about the anti-counterfeiting proposals contained in the European Commission's recently-released 'pharmaceutical package.'
GSK ceases political contributions
GlaxoSmithKline (GSK) is stopping making corporate political contributions as part of its transparency drive but employees can still donate through the Political Action Committee (PAC).